Nanogen, Inc., global developer of molecular diagnostic test kits, announced remarkable revenue and cost figures for the third quarter of 2008. Not only did revenues increase by a whopping 64% to $13.8 million compared to the same quarter in 2007, the company also managed to slash sales costs by 31%. The combination has accelerated the company’s move to profitability, especially in light of the recently announced plans to merge next year with French diagnostics company Elitech.